Empresa Antibe Therapeutics Inc Toronto S.E.
Acciones
ATE
CA0370251039
Biotecnología e investigación médica
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 01/12/15 |
Chief Tech/Sci/R&D Officer | - | - | |
Ana Stegic
CTO | Chief Tech/Sci/R&D Officer | - | - |
Scott Curtis
COO | Chief Operating Officer | - | 01/01/16 |
Joseph Stauffer
CTO | Chief Tech/Sci/R&D Officer | 58 | 06/05/20 |
Investor Relations Contact | - | - | |
David Vaughan
PRN | Corporate Officer/Principal | 74 | 01/11/12 |
Corporate Officer/Principal | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Director/Board Member | 50 | 24/11/20 | |
Amal Khouri
BRD | Director/Board Member | - | 19/03/18 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 53 009 362 | 48 481 043 ( 91,46 %) | 0 | 91,46 % |
Información de la empresa
Antibe Therapeutics, Inc.
15 Prince Arthur Avenue
M5R 1B2, Toronto
+416-922-3460
http://www.antibethera.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
+9,44 % | 115 mil M | |
+12,81 % | 107 mil M | |
-13,25 % | 22,31 mil M | |
-3,78 % | 21,6 mil M | |
-5,12 % | 18,23 mil M | |
-38,57 % | 17,62 mil M | |
+7,25 % | 14,26 mil M | |
+35,24 % | 12,37 mil M | |
-26,40 % | 8281,14 M |